A new executive order signed Tuesday by President Trump directs Congress to change a key provision of the law allowing Medicare drug price negotiations, a move that would fix one of the drug industry’s biggest complaints.

Many of the directions included in the order will be familiar to those who watched drug pricing policy closely during the first Trump Administration, though the portions of the order relating to the Inflation Reduction Act’s Medicare drug price negotiation program are more novel.